. 2017 Aug 10;8(45):78633–78641. doi: 10.18632/oncotarget.20203

Table 3. Multivariate analyses of the correlation between SNPs and treatment efficacy at the end of radiotherapy.

SNPs	Genotypes	Primary tumor efficacy¹ (n=174)					Lymph node efficacy¹ (n=144)
		CR²	Non-CR²	OR	95%CI	P	CR²	Non-CR²	OR	95%CI	P
XRCC1 rs25489	GG:GA	111/25/4	18/14/2	3.833	1.512-9.714	0.005	95/26/4	15/4/0	0.818	0.199-3.358	0.780
	GG:AA			2.552	0.360-18.088	0.348			-	-	-
	GG:(GA+AA)			3.610	1.496-8.713	0.004			0.699	0.174-2.813	0.615
	(GG+GA):AA			1.764	0.257-12.110	0.564			-	-	-
OGG1 rs1052133	CC:CG	42/68/30	15/15/4	0.552	0.227-1.344	0.191	45/58/22	5/9/5	1.922	0.518-7.128	0.329
	CC:GG			0.263	0.073-0.951	0.042			2.832	0.605-13.252	0.186
	CC:(CG+GG)			0.454	0.195-1.053	0.066			2.161	0.629-7.430	0.221
	(CC+CG):GG			0.371	0.114-1.209	0.100			1.895	0.532-6.745	0.324
APE(X)1 rs1130409	TT:TG	51/74/15	17/14/3	0.853	0.348-2.088	0.728	47/65/13	9/8/2	0.592	0.179-1.963	0.392
	TT:GG			0.392	0.088-1.749	0.220			0.698	0.107-4.570	0.708
	TT:(TG+GG)			0.719	0.310-1.667	0.442			0.615	0.203-1.865	0.390
	(TT+TG):GG			0.420	0.099-1.786	0.240			0.862	0.139-5.331	0.873

¹ Adjusted for age, gender, drinking, smoking, family history, BMI, TNM stage, clinical stage, treatment and EBV-DNA.

² Wild homozygote / heterozygote / mutant homozygote.

SNPs, single nucleotide polymorphisms; CR, complete remission; OR, odds ratio; 95%CI, 95% confidence interval.

P values < 0.05 are shown in bold.